DUBLIN, Nov. 10, 2015 /PRNewswire/ -- Research and Markets (http://www.researchandmarkets.com/research/jh757f/global_licensing) has announced the addition of the "Global Licensing Terms & Agreements in Pharma, Biotech & Diagnostics 2011-2015" report to their offering.
The Global Licensing Terms & Agreements in Pharma, Biotech & Diagnostics 2011-2015 report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the worlds leading life science companies.
The report provides a detailed understand and analysis of how and why companies enter licensing deals.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
Global Licensing Terms & Agreements in Pharma, Biotech & Diagnostics 2011-2015 includes:
In Global Licensing Terms & Agreements in Pharma, Biotech & Diagnostics 2011-2015 available deals and contracts are listed by:
Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.
For more information visit
http://www.researchandmarkets.com/research/jh757f/global_licensing
Media Contact:
Laura Wood, +353-1-481-1716, [email protected]
SOURCE Research and Markets
Share this article